Global Migraine Market: Industry Analysis & Outlook (2018-2022)

  • ID: 4559072
  • Report
  • Region: Global
  • 75 pages
  • Koncept Analytics
1 of 5
Development of Migraine Prevention Drugs to Spearhead Global Migraine Market

FEATURED COMPANIES

  • Alder Biopharmaceuticals
  • Amgen Inc.
  • Eli Lilly and Company
  • Teva Pharmaceuticals
  • MORE
Migraine is a chronic neurologic disease characterized by severe recurrent headaches. It is one of the most common and most prevalent disabling neurological conditions, characterized by episodes often called migraine attacks. They are quite different from regular headaches which are non-migrainous. Migraineurs generally have a lower threshold to triggers that might cause neuronal hyperexcitability, including sleep disturbances, environmental or emotional challenges, alcohol exposure, diet, and hormonal cycles/changes, among others.

Migraine headache is typically throbbing, unilateral (one sided), and is aggravated by physical activity. It typically presents with additional symptoms in addition to headache pain, including nausea, and sensitivity to light and/or sound.

Depending on symptoms, migraine is broadly classified into two categories, Chronic and Episodic. Migraines can be treated with two types of drugs: pain-relieving and preventive. Pain-relieving medications are especially useful for people who have nausea or vomiting related to their migraine, and they work quickly. Preventive treatment is considered if migraine occurs frequently, typically more than one migraine per week, or if migraine symptoms are severe.

The global migraine market is expected to grow in future due to increasing female population, rising health expenditure, accelerating economic growth, increasing cigarette consumption, rising prevalence of migraine and unmet needs. Key trends of this market include development of migraine drugs and growing awareness regarding migraine and its treatments. However, there are some factors which can hinder the growth of migraine market which includes regulatory challenges, high cost, adverse effects of drugs, lack of proper diagnosis and increased preference of alternative therapies.

The report “Global Migraine Market: Industry Analysis & Outlook (2018-2022)” provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, with focus majorly on the U.S. market. The report profiles the key players of the market including Amgen Inc., Eli Lilly and Company, Teva Pharmaceuticals & Alder Biopharmaceuticals.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Alder Biopharmaceuticals
  • Amgen Inc.
  • Eli Lilly and Company
  • Teva Pharmaceuticals
  • MORE
1. Overview
1.1 Introduction
1.2 Types
1.3 Stages
1.4 Diagnosis
1.5 Treatment

2. Global Market Analysis
2.1 Global Migraine Market by Value
2.2 Global Migraine Market Forecast by Value
2.3 Global Migraine Market by Drug Type
2.4 Global Therapeutic Botulinum Toxin Market Forecast by Value
2.5 Global Therapeutic Botulinum Toxin Market by Indication

3. Regional Market
3.1 The U.S.
3.1.1 The U.S. Migraine Population Forecast
3.1.2 The U.S. Diagnosed & Treated Adult Migraine Population
3.1.3 The U.S. Migraine Population with CV Risk Factors
3.1.4 The U.S. Migraine Treatment by Specialty
3.1.5 The U.S. Migraine Treated Population by Drug Type
3.1.6 The U.S. Acute Migraine Prescription Volume
3.1.7 The U.S. Migraine Prophylaxis Market by Treatment
3.2 The U.S. Migraine Drugs Revenue
3.2.1 The U.S. Botox Migraine Revenue and Treated Patients
3.2.2 The U.S. Cambia Drug Revenue
3.2.3 The U.S. Lasmiditan Drug Revenue & Treated Patients
3.2.4 The U.S. Alder Drug Revenue
3.2.5 The U.S. Erenumab Drug Revenue and Treated Patients
3.2.6 The U.S. Galcanezumab Drug Revenue and Treated Patients
3.2.7 The U.S. Fremanezumab Drug Revenue and Treated Patients
3.3 Europe
3.3.1 Europe Total Migraine and Diagnosed Population
3.4 Europe Migraine Drug Revenue
3.4.1 Europe Alder Drug Revenue

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Growing Female Population
4.1.2 Increasing Cigarette Consumption
4.1.3 Accelerating Economic Growth
4.1.4 Increasing Healthcare Spending
4.1.5 Rising Prevalence of Migraine Cases
4.1.6 Unmet Needs
4.2 Key Trends & Development
4.2.1 Migraine Drugs under Development
4.2.2 Growing Awareness for Migraine
4.3 Challenges
4.3.1 Adverse Effects of Drugs
4.3.2 Lack of Proper Diagnosis
4.3.3 Increased Preference for Alternative Therapies
4.3.4 Regulatory Challenges
4.3.5 High Cost Associated

5. Competition
5.1 Global Market
5.1.1 Global Migraine Market- Revenue Comparison of Key Companies
5.1.2 Global Migraine Market- Market Cap Comparison of Key Companies
5.1.3 Global Migraine Market- R&D Comparison of Key Companies

6. Company Profiles
6.1 Amgen Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Eli Lilly and Company
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Teva Pharmaceuticals
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Alder Biopharmaceuticals
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies

List of Charts
  • Types of Migraine
  • Global Migraine Market by Value (2013-2017)
  • Global Migraine Market Forecast by Value (2018-2022)
  • Global Migraine Market by Drug Type (2017)
  • Global Therapeutic Botulinum Toxin Market Forecast by Value (2017-2022)
  • Global Therapeutic Botulinum Toxin Market by Indication (2017)
  • The U.S. Migraine Population Forecast (2017-2022)
  • The U.S. Diagnosed and Treated Adult Migraine Population (2017-2022)
  • The U.S. Migraine Population with CV Risk Factors (2017-2022)
  • The U.S. Migraine Treatment by Specialty (2017)
  • The U.S. Migraine Treated Population by Drug Type (2017)
  • The U.S. Acute Migraine Prescription Volume (2017-2022)
  • The U.S. Migraine Prophylaxis Market by Treatment (2017)
  • The U.S. Botox Migraine Revenue and Treated Patients (2017-2022)
  • The U.S. Cambia Drug Revenue (2017-2022)
  • The U.S. Lasmiditan Drug Revenue & Treated Patients (2018-2022)
  • The U.S. Alder Drug Revenue (2019-2024)
  • The U.S. Erenumab Drug Revenue and Treated Patients (2018-2022)
  • The U.S. Galcanezumab Drug Revenue and Treated Patients (2019-2024)
  • The U.S. Fremanezumab Drug Revenue and Treated Patients (2019-2024)
  • Europe Total Migraine and Diagnosed Population (2017-2022)
  • Europe Alder Drug Revenue (2021-2026)
  • Global Female Population (2013-2017)
  • Global Cigarette Consumption (2014-2017)
  • Global GDP Per Capita (2013-2017)
  • Global Healthcare Spending Per Capita (2013-2017)
  • Global Migraine Market-Revenue Comparison of Key Companies (2017)
  • Global Migraine Market- Market Cap Comparison of Key Companies (2017)
  • Global Migraine Market- R&D Comparison of Key Companies (2017)
  • Amgen Inc. Revenue by Geographic Region (2017)
  • Amgen Inc. Revenue and Net Income (2013-2017)
  • Amgen Inc. Research and Development Expenditure (2015-2017)
  • Eli Lilly and Company Revenue by Segments (2017)
  • Eli Lilly and Company Revenue and Net Income (2013-2017)
  • Eli Lilly and Company Research and Development Expenditure (2015-2017)
  • Teva Pharmaceuticals Revenue by Segments (2017)
  • Teva Pharmaceuticals Revenue and Net Income (2013-2017)
  • Alder Biopharmaceuticals Revenue and Net Income (2013-2017)
  • Alder Biopharmaceuticals Research & Development Expenditure (2015-2017)
List of Tables
  • Difference between Episodic and Chronic Migraine
  • Stages of Migraine
  • Migraine Drugs under Development (2017)
  • Alder Pharmaceuticals Pipeline Overview (2017)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amgen Inc.
  • Eli Lilly and Company
  • Teva Pharmaceuticals
  • Alder Biopharmaceuticals
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll